Document:

Long term incentive agreement between the Company and Jenna Lyons

 Exhibit 10.41 
 

 
       April 24, 2006 
 Dear Jenna, 
 In connection with your continued employment by
J.Crew (the “Company”) and in recognition of your key contributions to the Company as its Senior Vice-President of Women’s Design, we are pleased to provide you the long-term incentive arrangement set forth in this letter. 

Provided that you remain continuously and actively employed by the Company and in good standing with the Company through each applicable payment,
grant and vesting date set forth below, and provided further that your individual performance continues to remain satisfactory to the Company as determined by it in its sole discretion through each such date, you will be eligible to receive a
long-term cash incentive and a restricted stock grant upon the terms described below. 
 1. Cash Incentive. Subject to the terms and
conditions of this letter, you will be entitled to receive up to Three Hundred Fifty Thousand Dollars ($350,000) (the “Cash Incentive”), payable in two equal installments as follows: (i) $175,000 on or about August 28, 2009, and
(ii) $175,000 on or about August 27, 2010 (each, a “Payment Date”). 
 2. Restricted Stock Grant. Subject to the
approval of the Compensation Committee of the Board of Directors and subject to the terms and conditions of this letter, the Company will also grant to you fifteen thousand (15,000) restricted shares of J.Crew Group, Inc. common stock (the
“Restricted Stock Grant”) as soon as practicable following the consummation of the proposed initial public offering of the Company (the “Grant Date”). The Restricted Stock Grant will vest in full and become exercisable on
August 1, 2010 (the “Vesting Date”). The terms and conditions of the Restricted Stock Grant will be evidenced by a separate restricted stock grant agreement to be signed by you and the Company and shall be subject to and consistent
with the terms and conditions of the Company’s equity incentive plan in effect on the Grant Date. 
 If your employment by the Company
terminates for any reason prior to either or both Payment Dates or prior to the Grant Date, you will no longer be entitled to receive the portion of the Cash Incentive that would have otherwise become payable on such Payment Date(s) or to receive
the Restricted Stock Grant. If your employment by the Company terminates for any reason after the Grant Date and prior to the Vesting Date, your Restricted Stock Grant will automatically be forfeited upon such termination. 
 Notwithstanding anything to the contrary contained in this letter, the terms of the Cash Incentive and the Restricted Stock Grant set forth herein are
subject to modification in the Company’s sole discretion if and to the extent necessary or appropriate to comply with any applicable deferred compensation laws which may become effective after the date hereof. 
 By reviewing and signing this letter, you understand that your employment by the Company remains “at will” and may be terminated by you or the
Company at any time and for any reason, and that this letter does not constitute an employment contract in any respect. 
 770 Broadway New
York NY 10003   Tel 212 209 2500   Fax 212 209 2666 

 If you agree with the terms of this letter, please sign and date the enclosed copy and return it to the
undersigned. You may keep the other copy for your records. 
 We are truly excited about you continuing to contribute to the Company’s
success as a valued associate! 
  

	
	Very truly yours,
	
	/s/    LYNDA MARKOE        
	Lynda Markoe
	SVP, Human Resources

  

	
	AGREED TO AND ACCEPTED:
	
	/s/    JENNA LYONS        
	Jenna LyonsSupplemental Octreotide CSR Agreement

 Exhibit 10.1 
 SUPPLEMENTAL OCTREOTIDE CONTINGENT STOCK RIGHTS AGREEMENT 
 THIS SUPPLEMENTAL OCTREOTIDE CONTINGENT
STOCK RIGHTS AGREEMENT (this “Supplemental Agreement”), dated as of March 23, 2009, is entered into by and among Indevus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Endo Pharmaceuticals Holdings
Inc., a Delaware corporation (“Endo”) and American Stock Transfer & Trust Company, as rights agent (the “Rights Agent”). 
 WHEREAS, the Company and the Rights Agent are parties to an Octreotide Contingent Stock Rights Agreement, dated as of April 17, 2007 (the “CSR Agreement”), pursuant to which the Company and the
Rights Agent made certain agreements with respect to certain contingent stock rights issued by the Company in connection with its acquisition of Valera Pharmaceuticals, Inc. (each such contingent stock right, a “CSR” and
collectively, the “CSRs”). Capitalized terms used herein and not defined herein have the meanings ascribed to such terms in the CSR Agreement; 
 WHEREAS, pursuant to Section 12(b) of the CSR Agreement, upon the merger of the Company with or into another corporation, there shall thereafter be deliverable upon conversion of any CSR in accordance with the
terms of the CSR Agreement the number of shares of stock or other securities, property or cash to which a holder of the number of shares of Indevus Common Stock that would otherwise have been deliverable upon the conversion of such CSR would have
been entitled upon such merger if the Milestone Date had occurred and such CSR had been converted in full immediately prior to such merger; 
 WHEREAS, on January 5, 2009, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Endo and BTB Purchaser Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned
subsidiary of Endo, pursuant to which, among other things, Merger Sub will be merged (the “Merger”) with and into the Company, with the Company continuing as the surviving corporation; 
 WHEREAS, in connection with the transactions contemplated by the Merger Agreement, Endo and American Stock Transfer & Trust Company, as paying
agent, have entered into the Nebido Cash Consideration Agreement and the Octreotide Cash Consideration Agreement, each dated as of February 23, 2009 (respectively, the “Nebido Cash Consideration Agreement” and the “Octreotide
Cash Consideration Agreement”), pursuant to which, upon the occurrence of certain regulatory and commercial milestones, Endo will make certain contingent cash consideration payments to former holders of Indevus Common Stock; 
 WHEREAS, pursuant to the Merger, the common stock of the Company shall be canceled and converted into the right to receive $4.50 per share, net in cash,
plus contractual rights to receive up to (1) $2.00 per share in contingent cash consideration payments pursuant to the Nebido 

 
Cash Consideration Agreement and (2) $1.00 per share in contingent cash consideration payments pursuant to the Octreotide Cash Consideration Agreement;

 WHEREAS, Section 12(c) of the CSR Agreement provides that a successor corporation to the Company shall expressly assume certain
obligations of the Company pursuant to a supplemental contingent stock rights agreement; 
 WHEREAS, pursuant to Section 12(b) of the
CSR Agreement, the board of directors of the Company has determined, in good faith, that the adjustment to the consideration payable pursuant to the CSRs set forth in Section 1.01(b) below is appropriate, which determination has been made in a
duly adopted resolution certified by the Secretary or Assistant Secretary of the Company; 
 WHEREAS, the execution and delivery of this
Supplemental Agreement has been duly authorized by each of the parties hereto and all conditions and requirements necessary to make this Supplemental Agreement a valid and binding agreement have been duly performed and complied with; and 

WHEREAS, pursuant to Section 6.14(b) of the Merger Agreement, this Supplemental Agreement is being executed and delivered prior to the
effectiveness of the Merger. 
 NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, it is mutually covenanted and agreed, for the equal and proportionate benefit of all registered Holders, as follows: 
 ARTICLE 1 
 COVENANTS 

 Section 1.01    Effect of Merger 
 Each of Endo and the Company agree and instruct the Rights Agent that the transactions contemplated by the Merger Agreement, including without limitation, the Merger and the cancellation and conversion of the
Company’s common stock pursuant to Section 3.1(a) of the Merger Agreement, shall be deemed to be a “Reorganization” within the meaning of Section 12(b) of the CSR Agreement. 
  

 2 

 Section 1.02    CSR Consideration 
 Each of Endo and the Company hereby agree and instruct Rights Agent that, notwithstanding the terms of Section 7(b) of the CSR Agreement and subject
to the other terms of the CSR Agreement, each CSR shall become convertible and shall entitle the Holder thereof, upon satisfaction of the procedures described in Section 8 of the CSR Agreement, after the Milestone Date and until 5:00 p.m., New
York City time, on the Termination Date, to receive from Endo or the Company only: 
 (a)    an amount in cash equal to
the product of (x) $4.50, in respect of the cash component of the consideration payable pursuant to the Merger, and (y) the quotient of (A) $1.50 divided by (B) the average of the per share closing sale prices of the common stock
of the Company as reported by the Nasdaq Global Market for the 10 trading days ending three trading days prior to the time at which the Merger becomes effective (such time, the “Effective Time”), rounded up to the fourth decimal
place (such quotient, the “Exchange Ratio”), 
 (b)    an amount in cash equal to the product of
(x) $1.00, in respect of the Octreotide Cash Consideration Payment component of the consideration payable pursuant to the Merger, and (y) the Exchange Ratio, 
 (c)    the contractual right, subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $2.00 and (y) the Exchange Ratio,
in the case that the Approval with Label Milestone Date (as defined in the Nebido Cash Consideration Agreement) occurs on or before February 23, 2012, 
 (d)    the contractual right, subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $1.00 and (y) the Exchange Ratio,
in the case that the Approval without Label Milestone Date (as defined in the Nebido Cash Consideration Agreement) occurs on or before February 23, 2012, and 
 (e)    the contractual right, subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $1.00 and (y) the Exchange Ratio,
in the case that the Net Sales Milestone Date (as defined in the Nebido Cash Consideration Agreement) occurs 
 The consideration described
in paragraphs (a) through (e) of this Section 1.02 is collectively referred to as the “CSR Consideration.” 
 Section 1.03    Ongoing Obligations 
 Effective as of the date hereof and immediately following the
effective time of the Merger, on the terms and subject to the conditions set forth herein, Endo does hereby: 
  

 3 

 (a)    accept and assume the Company’s obligation under the CSR Agreement to
provide the CSR Consideration, and 
 (b)    agree to perform and observe each and every covenant, condition, obligation
and liability under the CSR Agreement to be performed and observed by the Company. 
 ARTICLE 2 
 MISCELLANEOUS 
 Section
2.01    Effectiveness 
 This Supplemental Agreement shall become effective as of the Effective Time (as defined in
the Merger Agreement) of the Merger. 
 Section 2.02    Effect of Supplemental Agreement 
 (a)    On the date hereof, the CSR Agreement shall be supplemented and amended in accordance herewith, and this Supplemental
Agreement shall form part of the CSR Agreement for all purposes, and the Holder of every CSR heretofore or hereafter authenticated and delivered under the CSR Agreement shall be bound thereby. 
 (b)    This Supplemental Agreement shall be deemed to be incorporated in, and made a part of, the CSR Agreement. The CSR Agreement,
as amended and supplemented by this Supplemental Agreement, shall be read, taken and construed as one and the same instrument and all provisions in the CSR Agreement shall remain in full force and effect in accordance with the terms thereof and as
amended and supplemented by this Supplemental Agreement. 
 Section 2.03    Severability 
 In case any one or more of the provisions contained in this Supplemental Agreement shall for any reason be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Supplemental Agreement, but this Supplemental Agreement shall be construed as if such invalid, illegal or unenforceable provision had never
been contained herein. 
 Section 2.04    Counterparts 
 This Supplemental Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an
original and all such counterparts shall together constitute but one and the same agreement. 
  

 4 

 Section 2.05    Notices 
 Any notice or demand authorized by this Supplemental Agreement or the CSR Agreement to be given or made by the Rights Agent or by any Holder to or on
Endo or the Company, or any notice pursuant to this Supplemental Agreement or the CSR Agreement to be given by the Company or by any Holder(s) to the Rights Agent, shall be sufficiently given when received by Endo or the Company or the Rights Agent
at their respective offices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given if delivered personally, sent via electronic mail (receipt confirmed), facsimile (receipt
confirmed) or sent by a nationally recognized overnight courier (providing proof of delivery) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): 
 To Endo or the Company: 
 Endo
Pharmaceuticals Holdings Inc. 
 100 Endo Boulevard 
 Chadds Ford, PA 19317 
 Fax No.: (610) 558-9864 
 Attention: Caroline B. Manogue, Esq. 
 and
with a copy to: 
 Skadden, Arps, Slate, Meagher & Flom LLP 
 Four Times Square 
 New York, New York
10036-6522 
 Fax No: (212) 735-2000 
 Attention: Eileen T. Nugent, Esq. 
 To the Rights Agent: 
 American Stock Transfer & Trust Company 
 6201 15th Avenue, 2nd Floor 
 Brooklyn, NY 11219 
 Fax: 718-921-8310 
 Attention: Marianela Patterson 
 Section 2.06    Rights Agent 
 In entering into this Supplemental Agreement, the Rights Agent shall be entitled to the benefit of every provision of the CSR Agreement relating to the conduct or affecting the liability of or affording protection to
the Rights Agent, whether or not elsewhere herein so provided. 
 Section 2.07    Beneficiaries 
 All covenants and provisions of this Supplemental Agreement by or for the benefit of the Company, the Rights Agent, Endo or any Holder shall bind and
inure to the benefit of their respective successors, assigns, heirs and personal representatives. Nothing in this Supplemental 

  

 5 

 
Agreement shall be construed to give to any person or corporation other than the Company, the Rights Agent, Endo and the Holders any legal or equitable
right, remedy or claim under this Supplemental Agreement; but this Supplemental Agreement shall be for the sole and exclusive benefit of the Company, the Rights Agent, Endo and the Holders 
 Section 2.08    Governing Law 
 THIS SUPPLEMENTAL AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. 
 [Signatures on following page] 
  

 6 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Agreement to be duly executed as of
the day and year first above written. 
  

			
	INDEVUS PHARMACEUTICALS, INC.
		
	By:	 	/S/ CAROLINE B. MANOGUE
		 	 Name: Caroline B. Manogue
 Title:
Secretary

		 	
	ENDO PHARMACEUTICALS HOLDING INC.
		
	By:	 	/S/ CAROLINE B. MANOGUE
		 	 Name: Caroline B. Manogue
 Title: Executive Vice
President, Chief Legal Officer and Secretary

		 	
	AMERICAN STOCK TRANSFER & TRUST COMPANY, as Rights Agent
		
	By:	 	/S/ ISAAC FREILICH
		 	 Name: Isaac Freilich
 Title: VP

 [Signature Page for Supplemental Octreotide Contingent Stock Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]